Risk of central lymph node metastasis in papillary thyroid carcinoma based on ultrasound ECI and serum CCL20 and IL-17A and construction of a nomogram model

Objective To determine whether ultrasound elastic contrast index (ECI), serum C-C motif chemokine ligand 20 (CCL20), interleukin-17A (IL-17A) are risk factors for central lymph node metastasis in papillary thyroid cancer and to construct a nomogram for predicting CLNM in PTC. Methods This retrospective study included 308 PTC patients from Xinxiang Central Hospital (January 2022-December 2024) who underwent routine ultrasonography with postoperative pathological confirmation. Patients were randomly split 7:3 into a training set (n=216) and an internal validation set (n=92), and further classified by CLNM pathology into metastatic and non-metastatic groups. Demographic, ultrasound, and serum biomarker data were collected. Candidate predictors were screened by univariable analysis and LASSO regression with 10-fold cross-validation, followed by multivariable logistic regression to identify independent risk factors. The model’s performance was evaluated using receiver operating characteristic curve (ROC), area under the curve (AUC), calibration curve, and decision curve analysis. Bootstrap internal validation was performed to assess model stability. Results In the training set, taller-than-wide shape, multifocality, irregular margins, microcalcifications, capsular invasion, and levels of ECI, TSH, CCL20, and IL-17A were higher in the metastasis group ( P < 0.05). ECI, CCL20, and IL-17A showed positive correlations with each other and with TSH, taller-than-wide shape, multifocality, margin status, calcification, and capsular invasion ( P < 0.05). Multivariate analysis confirmed TSH, tumor size, margin, calcification, capsular invasion, ECI, CCL20, and IL-17A as independent risk factors for CLNM. ROC analysis yielded exploratory cut-off values of 3.35 for ECI, 65.21 ng/L for CCL20, and 24.61 pg/mL for IL-17A, with AUC of 0.746, 0.768, and 0.783, respectively. The nomogram showed apparent AUC of 0.960 (95% CI : 0.938-0.982) in the training set and 0.962 (95% CI : 0.929-0.994) in the internal validation set. Calibration and decision curve analysis were favorable. Bootstrap internal validation yielded an optimism-corrected AUC of 0.942; however, because variable selection was not repeated within each resample, this estimate is optimistic and true out-of-sample performance may be lower. Conclusion ECI, CCL20, IL-17A, TSH, and specific ultrasound features are risk factors for CLNM in PTC. The nomogram showed preliminary apparent performance, but external multicenter validation is required before clinical application.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-19
DOI
https://doi.org/10.3389/fonc.2026.1786471
Primary Topic
Thyroid Cancer Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Risk of central lymph node metastasis in papillary thyroid carcinoma based on ultrasound ECI and serum CCL20 and IL-17A and construction of a nomogram model

Yuan Li, Ting Dong, Jianling Li, Xueyun Yang et al.
Frontiers in Oncology
Thyroid Cancer Diagnosis and Treatment
article

Risk of central lymph node metastasis in papillary thyroid carcinoma based on ultrasound ECI and serum CCL20 and IL-17A and construction of a nomogram model

Yuan Li, Ting Dong, Jianling Li, Xueyun Yang, Huiyuan Li
article en

Abstract

Objective To determine whether ultrasound elastic contrast index (ECI), serum C-C motif chemokine ligand 20 (CCL20), interleukin-17A (IL-17A) are risk factors for central lymph node metastasis in papillary thyroid cancer and to construct a nomogram for predicting CLNM in PTC. Methods This retrospective study included 308 PTC patients from Xinxiang Central Hospital (January 2022-December 2024) who underwent routine ultrasonography with postoperative pathological confirmation. Patients were randomly split 7:3 into a training set (n=216) and an internal validation set (n=92), and further classified by CLNM pathology into metastatic and non-metastatic groups. Demographic, ultrasound, and serum biomarker data were collected. Candidate predictors were screened by univariable analysis and LASSO regression with 10-fold cross-validation, followed by multivariable logistic regression to identify independent risk factors. The model’s performance was evaluated using receiver operating characteristic curve (ROC), area under the curve (AUC), calibration curve, and decision curve analysis. Bootstrap internal validation was performed to assess model stability. Results In the training set, taller-than-wide shape, multifocality, irregular margins, microcalcifications, capsular invasion, and levels of ECI, TSH, CCL20, and IL-17A were higher in the metastasis group ( P < 0.05). ECI, CCL20, and IL-17A showed positive correlations with each other and with TSH, taller-than-wide shape, multifocality, margin status, calcification, and capsular invasion ( P < 0.05). Multivariate analysis confirmed TSH, tumor size, margin, calcification, capsular invasion, ECI, CCL20, and IL-17A as independent risk factors for CLNM. ROC analysis yielded exploratory cut-off values of 3.35 for ECI, 65.21 ng/L for CCL20, and 24.61 pg/mL for IL-17A, with AUC of 0.746, 0.768, and 0.783, respectively. The nomogram showed apparent AUC of 0.960 (95% CI : 0.938-0.982) in the training set and 0.962 (95% CI : 0.929-0.994) in the internal validation set. Calibration and decision curve analysis were favorable. Bootstrap internal validation yielded an optimism-corrected AUC of 0.942; however, because variable selection was not repeated within each resample, this estimate is optimistic and true out-of-sample performance may be lower. Conclusion ECI, CCL20, IL-17A, TSH, and specific ultrasound features are risk factors for CLNM in PTC. The nomogram showed preliminary apparent performance, but external multicenter validation is required before clinical application.

Frontiers in OncologyVol. 16
First Affiliated Hospital of Xinxiang Medical University (CN), Xinxiang Central Hospital (CN), Henan Medical University (CN)
Thyroid Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon